1: Limonciel A, Moenks K, Stanzel S, Truisi GL, Parmentier C, Aschauer L, Wilmes A, Richert L, Hewitt P, Mueller SO, Lukas A, Kopp-Schneider A, Leonard MO, Jennings P. Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Jan 13. pii: S0887-2333(14)00251-3. doi: 10.1016/j.tiv.2014.12.011. [Epub ahead of print] PubMed PMID: 25596134.
2: Jennings P. "The future of in vitro toxicology". Toxicol In Vitro. 2014 Oct 17. pii: S0887-2333(14)00189-1. doi: 10.1016/j.tiv.2014.08.011. [Epub ahead of print] Review. PubMed PMID: 25450745.
3: Aschauer L, Limonciel A, Wilmes A, Stanzel S, Kopp-Schneider A, Hewitt P, Lukas A, Leonard MO, Pfaller W, Jennings P. Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: A transcriptomic study. Toxicol In Vitro. 2014 Oct 23. pii: S0887-2333(14)00194-5. doi: 10.1016/j.tiv.2014.10.005. [Epub ahead of print] PubMed PMID: 25450743.
4: Jennings P. Stress response pathways, toxicity pathways and adverse outcome pathways. Arch Toxicol. 2013 Jan;87(1):13-4. doi: 10.1007/s00204-012-0974-4. Epub 2012 Nov 13. PubMed PMID: 23149676.
5: Jennings P, Limonciel A, Felice L, Leonard MO. An overview of transcriptional regulation in response to toxicological insult. Arch Toxicol. 2013 Jan;87(1):49-72. doi: 10.1007/s00204-012-0919-y. Epub 2012 Aug 28. Review. PubMed PMID: 22926699.
6: Jennings P, Schwarz M, Landesmann B, Maggioni S, Goumenou M, Bower D, Leonard MO, Wiseman JS. SEURAT-1 liver gold reference compounds: a mechanism-based review. Arch Toxicol. 2014 Dec;88(12):2099-133. doi: 10.1007/s00204-014-1410-8. Epub 2014 Nov 14. PubMed PMID: 25395007.
Paul Jennings is a senior scientist at the Division of Physiology, Medical University of Innsbruck.
He has 19 years experience in the field of renal in vitro methodologies and cell physiology, and has currently 60 publications related to the field.
His research is focused to understanding the molecular mechanisms of chemical induced nephrotoxicity with a strong focus on stress response pathways including but not limited to Nrf2, unfolded protein response and p53.
Current models employed in his laboratory include primary human proximal tubule (PT) cells, telomerase immortalised human PT cells (RPTEC/TERT1) and human iPSC derived PT and podocyte cells.
His laboratory is experienced in integrated omic analysis and biokinetics.
Dr. Jennings’ research group is an integral member of several key European Projects which aim to improve drug safety assessment regimes including, CarcinoGENOMICS, Predict-IV, DETECTIVE and StemBANCC.